Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
JYLAMVO vs CLOLAR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
JYLAMVO (methotrexate) is a folate analog that inhibits dihydrofolate reductase (DHFR), thereby disrupting DNA synthesis and repair. It also inhibits purine and thymidylate synthesis, leading to immunosuppressive and antineoplastic effects.
Clolar (clofarabine) is a purine nucleoside antimetabolite that inhibits DNA synthesis and RNA transcription. It is phosphorylated intracellularly to its active triphosphate form, which competes with adenosine triphosphate for incorporation into DNA, leading to chain termination and inhibition of DNA polymerase and ribonucleotide reductase, resulting in apoptosis.
Treatment of severe, active rheumatoid arthritis in adults,Treatment of polyarticular-course juvenile idiopathic arthritis in children,Treatment of severe psoriasis in adults
FDA: Treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) in pediatric patients aged 1 to 21 years.,Off-label: Treatment of acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), chronic myeloid leukemia (CML) in blast crisis.
Oral: 30 mg twice daily for adults with relapsed or refractory acute myeloid leukemia (AML) as a monotherapy.
5 mg/m2 intravenously over 2 hours daily for 5 consecutive days. Repeat every 28 days.
Terminal elimination half-life is 12-16 hours in adults with normal renal function; prolonged to 24-48 hours in severe renal impairment (Cr Cl <30 m L/min).
Terminal elimination half-life approximately 5.2 hours in patients with normal renal function; prolonged in renal impairment (up to 9.8 hours with Cr Cl <60 m L/min) and in elderly; clinical context: supports once-daily dosing adjustment for renal function.
Methotrexate is primarily metabolized in the liver to polyglutamated forms, which are retained intracellularly. It undergoes hepatic metabolism via aldehyde oxidase and xanthine oxidase. Renal excretion is the major elimination route.
Clofarabine is partially metabolized by deamination via cytidine deaminase (CDA) to inactive 6-keto-clofarabine. Approximately 50-60% of the drug is excreted unchanged in urine.
Primarily renal elimination as unchanged drug (approximately 70-80%) with minor biliary/fecal excretion (20-30%).
Renal: 50-60% as unchanged drug; biliary/fecal: minimal (<5%)
Approximately 85-90% bound primarily to albumin and alpha-1-acid glycoprotein.
47% bound to human plasma proteins, primarily albumin.
Volume of distribution is 0.6-1.2 L/kg, indicating distribution into total body water and some tissue binding.
Central Vd approximately 172 L/m² (extensive tissue distribution); in L/kg: ~4.6 L/kg (assuming 70 kg patient with BSA 1.73 m²). Clinical meaning: indicates wide distribution into total body water and tissues, exceeding total body water.
Oral bioavailability is 60-75% due to first-pass metabolism; absolute bioavailability is 70%.
Intravenous: 100% (only route of administration); oral: not available (no oral formulation).
No dose adjustment is recommended for patients with mild to moderate renal impairment (Cr Cl ≥30 m L/min). For severe renal impairment (Cr Cl 15-29 m L/min), reduce dose to 20 mg twice daily. For end-stage renal disease (Cr Cl <15 m L/min) or on dialysis, not recommended due to lack of data.
Cr Cl >= 60 m L/min: no adjustment. Cr Cl 30-59 m L/min: reduce dose by 20%. Cr Cl < 30 m L/min: contraindicated.
For patients with mild hepatic impairment (Child-Pugh A), no dose adjustment. For moderate hepatic impairment (Child-Pugh B), reduce dose to 20 mg twice daily. For severe hepatic impairment (Child-Pugh C), not recommended.
No specific guidelines; use caution in severe hepatic impairment (Child-Pugh class C) and consider dose reduction based on tolerability.
Safety and efficacy in pediatric patients have not been established; no recommended dosage.
1-21 years: 5 mg/m2 IV over 2 hours daily for 5 days every 28 days; reduce dose by 50% in patients with renal impairment.
No specific dose adjustment required based on age alone; monitor for increased risk of adverse events (e.g., myelosuppression, infections) as elderly patients may have decreased organ function and comorbidities.
No specific dose adjustment, but monitor renal function closely due to age-related decline and increased risk of toxicity.
JYLAMVO can cause severe or fatal toxicities including hepatotoxicity, myelosuppression, pulmonary fibrosis, and renal failure. It is contraindicated in pregnancy (teratogenic) and in nursing mothers. Fatal toxicity has been reported with concomitant NSAID use. Monitoring for toxicity and appropriate dosing adjustments are required.
WARNING: HEMATOLOGIC TOXICITY, INFECTION, AND HEPATIC TOXICITY. Clolar suppresses bone marrow function, causing severe neutropenia, thrombocytopenia, and anemia. Fatal infections have occurred. Hepatic toxicity, including hepatic failure and death, has been reported. Monitor blood counts and liver function frequently.
Hepatotoxicity (monitor liver function), myelosuppression (monitor CBC), pulmonary toxicity (interstitial pneumonitis), renal toxicity (monitor renal function), gastrointestinal toxicity, neurotoxicity, infections, and tumor lysis syndrome. Corticosteroids or other immunosuppressants may increase risk of infection.
Bone marrow suppression: severe neutropenia, thrombocytopenia, and anemia require close monitoring. Infections: serious and fatal infections (bacterial, fungal, viral) may occur. Hepatic toxicity: elevation of liver enzymes, bilirubin, and hepatic veno-occlusive disease. Renal toxicity: increased creatinine, hematuria, and hemolytic uremic syndrome-like reactions. Cardiac toxicity: pericardial effusion, hypotension, and ventricular dysfunction. Tumor lysis syndrome. Hypersensitivity reactions. Use in pregnancy: embryo-fetal toxicity. Vaccination: avoid live vaccines.
Hypersensitivity to methotrexate, severe hepatic impairment, severe renal impairment, severe anemia, leukopenia, thrombocytopenia, pregnancy, breastfeeding, alcoholism, pre-existing immunodeficiency syndromes, and concurrent use of NSAIDs in patients with renal impairment.
Absolute: Hypersensitivity to clofarabine or any component of the formulation. Relative: Severe hepatic impairment (bilirubin >3 mg/d L or transaminases >5x ULN). Severe renal impairment (creatinine clearance <30 m L/min).
No specific food interactions are known. Administer without regard to meals. Maintain adequate hydration.
No specific food interactions are documented. However, maintain adequate hydration to reduce risk of nephrotoxicity and tumor lysis syndrome. Avoid grapefruit and grapefruit juice as they may affect metabolism via CYP3A4 (theoretical concern, though clofarabine is primarily renally excreted).
JYLAMVO (methotrexate) is contraindicated in pregnancy. It is an abortifacient and teratogen. First trimester exposure causes multiple congenital anomalies (craniofacial, limb, CNS defects) and spontaneous abortion. Second and third trimester use may cause fetal growth restriction, developmental delay, and potential methotrexate syndrome. Use effective contraception during and for at least 3 months after treatment.
Clofarabine is contraindicated in pregnancy. Based on its mechanism of action (inhibitor of DNA synthesis) and animal studies, there is a high risk of fetal harm if administered during pregnancy. In the first trimester, there is a significant risk of embryolethality and teratogenicity (structural anomalies). In the second and third trimesters, fetal growth restriction and central nervous system damage may occur. Pregnancy must be excluded before initiation.
Contraindicated during breastfeeding. Methotrexate is excreted into breast milk in low concentrations (M/P ratio 0.6-1.1), but due to potential for serious adverse effects (immunosuppression, neutropenia, developmental toxicity) in the nursing infant, breastfeeding is not recommended. Discontinue breastfeeding or avoid JYLAMVO.
No data available on the excretion of clofarabine into breast milk or its effects on the nursing infant. Due to potential for serious adverse reactions (e.g., myelosuppression, gastrointestinal toxicity), breastfeeding is contraindicated during therapy and for at least 3 months after the last dose. M/P ratio is unknown.
Not applicable. JYLAMVO is contraindicated in pregnancy. No dose adjustments exist as it should not be used during pregnancy. Discontinue immediately if pregnancy occurs.
There are no established dose adjustments for clofarabine during pregnancy, as use is contraindicated. Physiological changes in pregnancy (e.g., increased plasma volume, altered renal clearance) may affect pharmacokinetics, but no dosing guidelines exist. If inadvertent exposure occurs, immediate discontinuation is recommended and the pregnancy should be managed by a maternal-fetal medicine specialist.
JYLAMVO (amivantamab) is a bispecific EGFR-MET antibody for EGFR exon 20 insertion mutation-positive NSCLC. Monitor for infusion-related reactions (premedicate with antihistamines, antipyretics, and corticosteroids). Assess for interstitial lung disease (ILD) prior to each dose; withhold for suspected ILD. Check serum albumin and electrolytes before treatment; hypoalbuminemia increases risk of toxicities. Advise use of sunscreen and sun protective measures due to photosensitivity risk.
Clolar (clofarabine) is a purine nucleoside analog indicated for pediatric relapsed/refractory acute lymphoblastic leukemia. Key pearls: (1) Monitor for systemic inflammatory response syndrome (SIRS) and capillary leak syndrome; premedicate with corticosteroids. (2) Requires aggressive hydration and allopurinol for tumor lysis prophylaxis. (3) Dose reductions needed for renal impairment (Cr Cl < 60 m L/min). (4) Avoid live vaccines during and after treatment.
JYLAMVO is given as an intravenous infusion over 2-4 hours, typically every 2 weeks after an initial loading dose.,You may experience infusion reactions; symptoms include fever, chills, nausea, or shortness of breath. Tell your nurse immediately if these occur.,This drug can cause lung inflammation (ILD); report any new or worsening cough, chest pain, or difficulty breathing.,Avoid prolonged sun exposure; use broad-spectrum sunscreen (SPF 30+) and wear protective clothing.,Your doctor will monitor your blood counts and kidney function regularly during treatment.
Clolar is a chemotherapy drug used to treat a type of leukemia in children that has not responded to other treatments.,You may experience side effects like fever, nausea, vomiting, diarrhea, and skin rashes. Report any signs of infection or unusual bleeding.,Drink plenty of fluids as directed to prevent kidney problems. You may receive IV fluids before and after treatment.,Avoid vaccinations without doctor approval, as live vaccines are not safe during treatment.,This drug can cause severe reactions including organ inflammation and fluid retention; seek immediate medical help if you have difficulty breathing, rapid weight gain, or swelling.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about JYLAMVO vs CLOLAR, answered by our medical review team.
JYLAMVO is a Antineoplastic Agent that works by JYLAMVO (methotrexate) is a folate analog that inhibits dihydrofolate reductase (DHFR), thereby disrupting DNA synthesis and repair. It also inhibits purine and thymidylate synthesis, leading to immunosuppressive and antineoplastic effects.. CLOLAR is a Antineoplastic Agent that works by Clolar (clofarabine) is a purine nucleoside antimetabolite that inhibits DNA synthesis and RNA transcription. It is phosphorylated intracellularly to its active triphosphate form, which competes with adenosine triphosphate for incorporation into DNA, leading to chain termination and inhibition of DNA polymerase and ribonucleotide reductase, resulting in apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between JYLAMVO and CLOLAR depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of JYLAMVO is: Oral: 30 mg twice daily for adults with relapsed or refractory acute myeloid leukemia (AML) as a monotherapy.. The standard adult dose of CLOLAR is: 5 mg/m2 intravenously over 2 hours daily for 5 consecutive days. Repeat every 28 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between JYLAMVO and CLOLAR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. JYLAMVO is classified as Category C. JYLAMVO (methotrexate) is contraindicated in pregnancy. It is an abortifacient and teratogen. First trimester exposure causes multiple congenital anomalies (craniofacial, limb, CNS. CLOLAR is classified as Category C. Clofarabine is contraindicated in pregnancy. Based on its mechanism of action (inhibitor of DNA synthesis) and animal studies, there is a high risk of fetal harm if administered du. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.